Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

PURPOSE: To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery or mastectomy. PATIENTS AND METHODS: Patients with early-stage resected human epidermal growth factor receptor 2 (HER-2) –positive breast cancer (BC) were randomly assigne...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Halyard, Michele Y., Pisansky, Thomas M., Dueck, Amylou C., Suman, Vera, Pierce, Lori, Solin, Larry, Marks, Larry, Davidson, Nancy, Martino, Silvana, Kaufman, Peter, Kutteh, Leila, Dakhil, Shaker R., Perez, Edith A.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2009
נושאים:
Original Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2690390/
https://ncbi.nlm.nih.gov/pubmed/19349549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.9549
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים